Xeloda and Bevacizumab to Treat Rectal Cancer
The project objective is to evaluate the efficacy of the neoadjuvant treatment with bevacizumab, capecitabine and radiotherapy, in patients with rectal adenocarcinoma resectable locally advanced (stage T3 or T4), with or without presence of ganglionar metastases and without distant metastases.
Rectal Cancer
BIOLOGICAL: Bevacizumab|DRUG: capecitabine (Xeloda)|RADIATION: Rectal Radiotherapy
Pathologic complete response rate. % patients with pathologic complete response (absence of tumoral cells in the resected piece), Surgery date
Overall clinical response, Surgery date|To determine the downstaging caused by treatment, Surgery date|relapse free survival, Time of radiological evidence of relapse.|Quantify the local control grade: R0 resections in surgery, Surgery date|Local relapse and distant relapse rates, Relapse date|To determine the security profile of this neoadjuvant treatment (radio- chemotherapy), From date of register to surgery date|Surgery complication rate, During surgery admission.|To determine the angiogenic profile changes in tumour., 15 days, 6 weeks and 4 months
The project objective is to evaluate the efficacy of the neoadjuvant treatment with bevacizumab, capecitabine and radiotherapy, in patients with rectal adenocarcinoma resectable locally advanced (stage T3 or T4), with or without presence of ganglionar metastases and without distant metastases.